Study of the efficacy of topical 25% benzyl benzoate versus 5%permethrin in patients with scabies

K f. Dermatologie und Allergologie Salzburg0 个研究点目标入组 110 人开始时间: 2023年1月18日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•- Scabies norvegica/crustosa
•- Pre-treatment of creams/emulsions containing benzyl benzoate (Antiscabiosum® 25%) in the last 3 weeks (from first application)
•- Application of creams containing permethrin (e.g. Infectoscab® 5%) during the last 3 weeks (from first application)
•- Use of oral ivermectin in the last 3 weeks.
•-- EXCEPTION: Children from the age of 12 to 18 years or study participants with a high mite density (>5 mites with duct structures in the reflected light microscope field of view) may be treated with topical benzyl benzoate, topical benzyl benzoate, topical benzyl benzoate, topical benzyl benzoate
•benzyl benzoate, topical permethrin or oral ivermectin may be included
•- known hypersensitivity to the active ingredient benzyl benzoate or permethrin
•- Patients who, because of their physical development or clinical condition, are unable to receive
•Are unable to understand and correctly perform the treatment procedures
•- Pregnancy and lactation
•- Alcohol abuse, mental retardation
•- Lack of willingness to comply/adhere to appointments as well as the
•Study protocol, and lack of understanding of the German language.

发起方

K f. Dermatologie und Allergologie Salzburg